Biotech Values

1,523

Biotech Values

1,523

Sticky

DewDiligence

APLS refinances debt:

Sticky

oc631

Just an observation on NVAX. They filed their

Sticky

DewDiligence

PFE expects_to_sell $3B of Paxlovid in 2024, even

Sticky

Mufaso

VKTX- Yes the options activity has been very

Sticky

Mufaso

VKTX cc on VK2735 was very well received

Sticky

DewDiligence

Over the years, I’ve found posts that verbalize

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Older

DewDiligence PremiumMember

05/14/24 5:44 PM

Post #251,821

Re: #251,697: @DewDiligence - AEON—(-53%)—reports failed phase-2 in migraine prevention:

AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.

DewDiligence PremiumMember

05/14/24 2:11 PM

Post #251,820

Re: #250,827: @DewDiligence - APLS management is making excuses vis-à-vis the Syfovre

APLS refinances debt:

https://finance.yahoo.com/news/apellis-pharmaceuticals-refinances-existing-debt-120000044.html

New $475M credit lines expiring in 2030 enable APLS to pay off debt due in 2027.

APLS’ Syfovre is not an especially good drug (#msg-173940338), but there is apparently no shortage of lenders to refinance debt of companies with FDA-approved products.

vinmantoo

05/14/24 11:51 AM

Post #251,818

Re: #251,810: @jbog - Whatalane, Vinny

Around 2017 I was having neck and back problems and went in for a MRI. The next morning my personnel doctor (not back doc) called and told me I was loaded with Kidney Cysts on the right side and wanted them investigated. After a couple tests they determined they were liquid filled rather than solid so I was basically in the clear.

During this time period I researched autosomal dominant polycystic kidney disease (ADPKD) and like Kiwi said, there's nothing out there. I did come across Regulis and the trials they were performing with a drug called RGLS4326 was showing very good P1 and P2 control. I bought a couple thousand share on a hunch at $7 per share.

After they finished their 3rd MAD dose,which the results were fantastic, the bad news hit. Some rodents in their pre-clinical data have exhibited toxicity after 4 years, Of course the stock crushed.

Regulis responded that they were able to find the problem and promised a fix. Soon after they came out with RGLS8429 which they promised would be safe and more powerful.

jbog, thanks for the detailed response. Glad your test were good news. I will take a closer look. All I knew before your comment is that they are using miRNA modulation as their MOA. That mechanism certainly presents possibilities of treatment of a broad spectrum of diseases. A long time ago I had a colleague who found a puzzling phenomenon, where a region down stream of a C. elegans gene was affecting expression of a different gene on another chromosome. It was puzzling because the down stream region didn't code for a protein and his career suffered. He didn't get tenure so had to move on to another University. Once it was discovered that the downstream region he was working on coded for a small RNA (i.e. miRNA), it made his career take off. Lots of serendipity in science. As far as RGLS, RGLS4326 is their only drug in trials so far. Any idea when they project other areas they are working will enter trials? I guess I need to listen to the latest CC. Good luck.

Thanks also to Kiwi as well for his response.

jbog

05/14/24 7:51 AM

Post #251,817

Re: #251,812: @Whalatane - Thx Jbog Just to be clear

Whalatane

Thx Jbog Just to be clear ...and it's none of my business so ignore if necessary ...the cysts were liquid filled ? I thought that was one of the markers of ADPKD

Because there's no easy way to treat the disease we're basically monitoring my Kidney Function through simple blood tests on a semi-annual basis. If I was younger and they found them because of a complaint treatment would be different. As a side note they also found a large (5cm) AAA aneurysm which they operated on right away.

good luck

Mufaso

05/14/24 7:02 AM

Post #251,816

VKTX- Blue Sky Scenario - "How Viking Therapeutics Stock Could 30x"

I continue to believe that VKTX offers an incredibly good risk reward profile. While I rarely find Motley Fool articles to be good, the one I quote below captures the "Blue Sky" math along with my current thinking that while a buyout is likely, a partnership specifically with PFE would be better and is the ultimate blue sky scenario for VKTX. I have highlighted in BLUE all of the comments I especially agree with from this article and one in RED at the end that anyone with or considering an investment in Viking should note:

Viking Therapeutics (NASDAQ: VKTX) has been one of the few bright spots in the healthcare sector this year. The biotech's shares have stormed higher by almost 300% year to date on the back of its midstage weight-loss candidate, VK2735. The lowdown is that VK2735 could be a top three weight-loss medication in terms of sales, according to some analyst estimates. That's a potentially incredible opportunity for risk-tolerant investors.

The weight-loss drug market could reach a staggering $158 billion in sales by 2032, per Leerink Partners. For a non-COVID product, the pharmaceutical industry has never witnessed such a massive commercial opportunity. Breaking this down further, VK2735 might be a $30 billion-a-year drug in the making, depending on how the competitive landscape shapes up, the drug's pivotal-stage data, and the trajectory of the out-of-control obesity epidemic.

After all, these next-generation weight loss drugs aren't only showing dramatic improvements in lipid profiles; they are exhibiting clear-cut cardiovascular and blood sugar control benefits as well. Why should investors take notice? With only a 3x handle, Viking could warrant a $90 billion market capitalization. It currently garners a market cap of just $8.12 billion. That's over 10x in market capitalization for those of you keeping score.

However, Viking stock could blow past the 10x mark to achieve 20x to over 30x returns for investors from this point. Think that sounds like a pipedream? Consider this. A realistic path to 30x gains:

Novo Nordisk stock presently trades at over 16 times trailing sales, whereas Eli Lilly's shares are exchanging hands at over 19 times trailing sales. Now, these are multinational pharma companies with broad pipelines outside of weight loss. But most of their premium valuation stems from their weight loss drugs Wegovy and Zepbound, respectively.

Extending this logic, Viking's stock, with only a 10x trailing sales valuation and a $30 billion-a-year product, would be worth $300 billion in market capitalization. That's nearly double Pfizer's (NYSE: PFE) current market capitalization, which sounds absurd. Viking is a pre-revenue biotech with a short operating history, after all. Pfizer, on the other hand, has been in existence since 1849. I know, these numbers sound outlandish, absurd even. However, math is indifferent to our preconceived notions of value.

A critical question and an overarching concern So, prospective investors should ask themselves this question: Is this a blue-sky scenario? I do not believe this is a blue-sky scenario in the least. If VK2735 can continue to post top levels of efficacy and safety, I suspect this mid-cap biotech stock may go on a historic run.

My bigger concern is management cashing out by selling the company before VK2735's pivotal data release a few years from now.Developmental-stage companies like Viking are at a distinct disadvantage when marketing newly launched drugs; so selling the company wouldn't necessarily be an unwise decision by management.

A better outcome for stakeholders would be for Viking to partner with big pharma on a co-commercialization agreement. And yes, I'm looking at you, Pfizer. It's no secret that Pfizer is on the hunt for a needle-moving obesity asset. Viking's brain trust may be willing to sell out early to lock in gains in case VK2735's story falls apart in the clinic. Clinical setbacks happen constantly in biopharma, and it is one reason investors have kept their distance from this space since interest rates flipped.

But a partnering agreement, post Phase 3 data release, with a Pfizer, or similar type of deep-pocketed pharma, would undoubtedly be the best path toward 20x to 30x gains for Viking's early shareholders.

Final thoughts
The bottom line is Viking might be poised to enter the pantheon of truly great growth stocks this decade. Of course, risk abounds with clinical-stage assets, and black swans are never far away from biopharma companies.

An unforeseen patent challenge, safety signal, or managerial mishap could send this promising obesity-case asset into the dustbin of history. If you're willing to take that chance, this biotech stock could be your ticket to life-changing gains.

Mufaso

05/14/24 6:12 AM

Post #251,815

Re: #251,811: @jbog - Wegovy weight loss sustained for four years in

A different take on the same study focused on the Heart benefits of Wegovy over time was on CNN. I found this article to be better or at least more interesting and put some quotes/comments below:

https://www.cnn.com/2024/05/13/health/wegovy-trial-analysis/index.html

“The implications are profound,” said Dr. Harlan Krumholz, a cardiologist and scientist at Yale University and Yale New Haven Hospital who was not involved in the research, noting that a second study this week showed a similar finding for heart failure. “We have not encountered a drug with such a breadth of heart benefits.”

More than 25,000 people in the US are starting Wegovy every week, drugmaker Novo Nordisk said this month. And in a KFF poll released Friday, 6% of respondents said they were currently using a drug in this class, known as GLP-1 receptor agonists. That translates to more than 15 million Americans.

One important question about these blockbuster medicines is how widely – and how long – they’ve been studied. The Select trial, which was funded by Novo Nordisk, showed last year that Wegovy reduced the risk of a heart attack, stroke or heart-related death by 20% in people with existing cardiovascular risk with obesity or who are overweight. It included more than 17,600 people from 41 countries between 2018 and 2021 and followed them for several years.

Results vary for everyone- In the new analysis, the researchers reported that after two years, about 68% of people taking Wegovy had lost at least 5% of their body weight, while 21% of people on a placebo did. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo. And almost 5% of people on the drug lost more than 25% of their body weight, compared with 0.1% on placebo, showing that the top-line findings from studies are just averages; everyone has a different experience with medicines.

I think your "NOT IMPRESSED" comment was related to Wegovy weight loss and given the new drugs that have come out (tirzepatide-mounjaro/zebound) and those in trials from VKTX,NVO,LLY,ALT and others - Wegovy weight loss is not that impressive. (I would agree with you on this point and the article you cited.) But in the context of decades of research where many companies looked for weight loss drugs that worked without harm (and were unsuccessful) it is amazing that semaglutide a mono agonist GLP1 is not only showing weight loss benefit but Cardio benefit beyond what could be attributed to the weight loss alone.

oc631

05/14/24 5:12 AM

Post #251,814

Re: #251,789: @oc631 - SNY must believe either that the NVAX platform

Just an observation on NVAX. They filed their 10-Q and the 8-K for their earnings release yet what's notably absent is the 8-K announcing the SNY deal (as of the time of this post). Anyone care to guess why?

Here's the belated 8-K

https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=318313470&type=HTML&symbol=NVAX&cdn=2f36774780bfe3a5d53cb140344a733d&companyName=Novavax+Inc.&formType=8-K&dateFiled=2024-05-13

The company is more forthright in their 8-K stating that SNY will become an active partner in the 2025/2026 season at the earliest. The co-commercialization agreement for covid-mono products appears [to me] to be an option but not an obligation for SNY to market Nuvaxovid. I see no language claiming SNY should use their "best efforts" in this regard. Twice in the above 8-K I see reference to a "commercialization plan [for covid-mono] agreed [to] by the Company and Sanofi" yet this commercialization plan is not disclosed. There's a slim chance competing covid/flu combos will start taking market share from mono products beginning this year and a much higher likelihood next. Will SNY begin to produce and market a covid mono product with declining market share? Nuvaxovid may be deemed non-competitive. The $175M milestone payment due upon approval of the mono product [in prefilled syringes] for the 25/26 season may very well be based on greenlighting the combo and have little to do with Nuvaxovid sales.

Questions to ponder: Will the FDA continue to grant covid EUA next season? What if Nuvaxovid isn't approved in the U.S. by the 2025/2026 season? If you have followed NVAX in the past don't say this can't happen.

Whalatane

05/13/24 10:14 PM

Post #251,813

Re: #251,810: @jbog - Whatalane, Vinny

Jbog. re your comment

The shares immediately jumped to $2.80 and has leaked down to the lower $2 level.

Last week they said they would raise another $50m ...ie dilute existing shareholders by about .45 c a share .
Just my layman's take
Data looks good ...so far
Kiwi
JMO

Whalatane

05/13/24 9:36 PM

Post #251,812

Re: #251,810: @jbog - Whatalane, Vinny

Thx Jbog Just to be clear ...and it's none of my business so ignore if necessary ...the cysts were liquid filled ? I thought that was one of the markers of ADPKD

You wrote
.

After a couple tests they determined they were liquid filled rather than solid so I was basically in the clear.

A Perplexity search
The cysts in autosomal dominant polycystic kidney disease (ADPKD) are fluid-filled sacs that develop within the kidneys.
The symptoms of ADPKD are caused by the growth of these fluid-filled cysts in the kidneys. As the cysts expand, they can cause the kidneys to become enlarged and gradually lose function over time.
The cyst fluid itself contains various substances that promote further cyst growth and expansion. Studies have shown that the cyst fluid stimulates cellular proliferation, fluid secretion, and cyst formation when added to cultured renal epithelial cells. The cyst fluid contains potent substances that augment biological processes leading to progressive cyst expansion in ADPKD.
So in summary, the hallmark of ADPKD is the development of numerous liquid-filled cysts within the kidneys, which are the primary cause of the disease manifestations and complications as the cysts progressively enlarge over time.

Kiwi

jbog

05/13/24 8:21 PM

Post #251,811

Re: #251,763: @Mufaso - Compounded GLP1's - Glad your brother has found

Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Maggie Fick
Mon, May 13, 2024, 7:52 PM EDT2 min read

By Maggie Fick

https://finance.yahoo.com/news/wegovy-weight-loss-sustained-four-235205788.html

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.

Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year.

"This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.

"We see that once the majority of the weight loss is accrued, you don't go back and start to increase in weight if you stay on the drug," he added.

The data could bolster the company's case as it tries to convince insurers and governments to reimburse Wegovy and deflect notions that it is a lifestyle drug.

Wegovy was the first to market from a newer generation of medicines known as GLP-1 agonists, originally developed for diabetes, that provide a new way to address record obesity rates. Eli Lilly launched its rival drug Zepbound in the United States in December. Neither company has been able to produce enough to meet unprecedented demand.

Dr. Simon Cork, Senior Lecturer in Physiology from Anglia Ruskin University, said Britain's public health service's decision to limit coverage of the medicine to two years was "because of questionable long-term effectiveness".

The new data showing benefits continuing to four years may go some way to negating that argument, he said.

The 17,604-patient trial tested Wegovy not for weight loss but for its heart protective benefits for overweight and obese patients who had preexisting heart disease but not diabetes. Participants were not required to track diet and exercise because it was not an obesity study.

Patients in the trial called Select lost an average of nearly 10% of their total body weight after 65 weeks on Wegovy. That percentage weight-loss was roughly sustained year-on-year until the end of about four years, where weight loss stood at 10.2%, the company said.

Wegovy and Zepbound are being tested to assess their benefits in a variety of other medical uses such as lowering heart attack risk and for sleep apnea and kidney disease.

The weight loss in the heart trial was less than the average of 15% weight loss in earlier Wegovy obesity studies before the drug was launched in the United States in June 2021.

NOT IMPRESSED

jbog

05/13/24 7:28 PM

Post #251,810

Re: #251,805: @Whalatane - Vin re RGLS . I

Whatalane, Vinny

Around 2017 I was having neck and back problems and went in for a MRI. The next morning my personnel doctor (not back doc) called and told me I was loaded with Kidney Cysts on the right side and wanted them investigated. After a couple tests they determined they were liquid filled rather than solid so I was basically in the clear.

During this time period I researched autosomal dominant polycystic kidney disease (ADPKD) and like Kiwi said, there's nothing out there. I did come across Regulis and the trials they were performing with a drug called RGLS4326 was showing very good P1 and P2 control. I bought a couple thousand share on a hunch at $7 per share.

After they finished their 3rd MAD dose,which the results were fantastic, the bad news hit. Some rodents in their pre-clinical data have exhibited toxicity after 4 years, Of course the stock crushed.

Regulis responded that they were able to find the problem and promised a fix. Soon after they came out with RGLS8429 which they promised would be safe and more powerful.

Over the years the stock was sub $1 so they had a reverse split 1:10. Last fall evenafter the split the stock was at 50=60 cents and I accumulated over 100K more shares. Kripe the Companies Market Cap was at $14mil.

They just reported the 2nd co-hart a couple of weeks ago with great results along with a strategic buyers putting up $112 Mil for more shares. The shares immediately jumped to $2.80 and has leaked down to the lower $2 level.

Bet you never heard of that before, but someone likes it. The 3rd Co-hart is enrolled and results should be out june-july.

They are running the last dose at a fixed level and then will talk to the FDA.

Please note, one of my other favorite companies, Vertex just announced they want to enter the field.

Whalatane

05/13/24 6:59 PM

Post #251,809

UNCY pivotal trial update

“This is an exciting time for Unicycive as we progress towards the conclusion of our pivotal clinical trial for our lead asset oxylanthanum carbonate (OLC),” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “The trial is evaluating the tolerability, safety, and pharmacokinetics of clinically effective doses of OLC in patients with chronic kidney disease (CKD) on dialysis and it remains on track with topline data expected later this quarter.

By my calculations this pivotal trial will end this weekend.
What remains is data checking / cleaning and then publishing results

Some background . High serum phosphorous is a continuing problem for most ( 85 % ) on dialysis due to kidney failure .
This is because almost all the patients currently taking the Pho binders hate them either because of taste ( chewed with meals ) or pill burden ( up to 12 pills a day )
Recently ARDX managed to get Xphazoh approved ...2 small pills swallowed not chewed ( one at breakfast , 1 at dinner ) While many Nephrologist want to try this drug there are 2 problems .
1) Diarrhea in half the patients for the first 2-3 wks
2) Cost if you are on Medicare / Medicaid . Medicare / Medicaid means patients can't use the coupons ARDX is currently handing out and their copay pay ( This is a tier 5 drug ) is roughly $1,000 a month .
None of the patients my wife's sees are willing to pay the copay as most are Medicare / Medicaid.

Now comes UNCY's OLC .
OLC is a new form of Fosrenol that they wife already prescribes if patients refuse Selevmar ( lowest priced generic )
The advantage of OLC is that its 1 small pill with each meal ...SWALLOWED ( this makes a difference re adherence ) ...not chewed or in powder form mixed with applesauce.
OLC is very effective at lowering serum Pho .
The problem is stomach upsets / nausea .
UNCY's final trial ..results due soon see above ..is all about tolerability .
Can they slowly increase the dose to gradually get serum Pho down to target and keep patients on the drug ?

My guess is that PPS will either drop to 50c or head towards $5 ...depending on results
Risk only what you can afford to lose and forget me if this fails ..:--)

Kiwi

Fred Kadiddlehopper Free

05/13/24 5:31 PM

Post #251,808

Re: #251,807: @DewDiligence - Ginkgo—The post I'm replying to aged pretty well.

Does this mean that they are no longer "the leading platform for cell programming and biosecurity"?

DewDiligence PremiumMember

05/13/24 4:44 PM

Post #251,807

Re: #238,033: @DewDiligence - Ginkgo/SRNG—Count me as a skeptic vis-à-vis the valuation.

Ginkgo—The post I'm replying to aged pretty well.

https://www.prnewswire.com/news-releases/ginkgo-bioworks-receives-continued-listing-standard-notice-from-nyse-302143891.html

rwwine

05/13/24 2:12 PM

Post #251,806

Re: #251,805: @Whalatane - Vin re RGLS . I

Thanks for sharing Kiwi. 😊

Whalatane

05/13/24 1:47 PM

Post #251,805

Re: #251,799: @vinmantoo - I lost my shirt and sold out at

Vin re RGLS . I have a small position in this Co and am also interested in why Jbog is high on it ?
Reasons for my position ?
Theres currently only 1 med available specific to ADPKD kidney disease and its poorly tolerated ( makes you pee a lot ) and not very effective.
There are around 160,000 ADPKD patients in the US and around 55% of them will have kidney failure and need dialysis by age 55.
My wife rounds dialysis clinics and writes reports on roughly 120 dialysis patients each month ..There is a high mortality rate for dialysis patients ...you can google or perplexity the numbers if you wish.
RGLS 's med slows the formation of cysts in the kidney filtration system and so far appears very safe and well tolerated.
This is P 1 data . P2 trials expected in 2025 will an expected application for accelerated approval .
So early days
Vivo Capital owns roughly 8% of the outstanding shares ( IIRC ) . Vivo specializes in a lot of niche kidney specific drugs in development ...UNCY for example
Kiwi

DewDiligence PremiumMember

05/13/24 12:44 PM

Post #251,804

Re: #251,271: @Mufaso - UPDATED-List of ORAL Weight loss candidates.

TERN-601:

https://finance.yahoo.com/news/terns-pharmaceuticals-reports-first-quarter-120500965.html

• Phase 1 first-in-human clinical trial of Terns’ lead oral GLP-1 receptor agonist in obese and overweight participants is progressing

• The multiple ascending dose (MAD) portion of the study is underway, testing once-daily administration of TERN-601, and is on track to report top-line 28-day weight loss data in the second half of 2024

• Preliminary safety findings from the ongoing, blinded Phase 1 SAD/MAD study have been unremarkable to date with no observations of liver enzyme elevations, drug induced liver injury or discontinuations due to treatment-related adverse events

Why is this compound in your less interesting, “May surprise” grouping? TIA

DewDiligence PremiumMember

05/13/24 12:33 PM

Post #251,803

Re: #251,640: @DewDiligence - Recent Biotech Buyouts of Publicly Traded Companies

Recent Biotech Buyouts of Publicly Traded Companies

[Added RPHM reverse-merger.]

Table entries are in descending order of buyout premium.
Reverse-mergers are listed at the bottom.

Acquired ‡Premium *Deal iHub
Company Buyer to Market Value Date Reference
LOGC AZN 667% $70M 10/22 #msg-170099482
TBRA AGN 498% $615M 9/16 #msg-125266132
AVRX CLDA 487% $8M 10/08 #msg-33212809
GNLB GSK 465% $57M 10/08 #msg-33209281
DMTX RARE 396% $167M 10/17 #msg-135053781
CMPI REGN 336% $250M 4/22 #msg-168585070
MEMY Roche 319% $50M 11/08 #msg-33787598
IMDZ MRK 311% $300M 2/19 #msg-147004924
SGTX LLY 280% $35M 6/23 #msg-172236626
PRVB SNY 273% $2.9B 3/23 #msg-171430824
KDS.AS SNY 272% $360M 11/20 #msg-159250085
ANDS Roche 256% $220M 10/11 #msg-68043946
SYNB PFE 240% $10M 12/10 #msg-58221573
IDIX MRK 239% $3.85B 6/14 #msg-103051902
KOSN BMY 233% $190M 5/08 #msg-29647147
ZYNE HRMY 226% $60M 8/23 #msg-172590073
MIRO UTHR 213% $91M 10/23 #msg-173118733
TRIL PFE 204% $2.3B 8/21 #msg-165570289
ACER ZVRA 203% $15M 8/23 #msg-172730826
TSRO GSK 182% $5.1B 12/18 #msg-145223384
VLA.AX MRK 182% $394M 2/18 #msg-138708052
SQNM LH 182% $367M 7/16 #msg-124139335
NSPH LMNX 179% $77M 5/16 #msg-122867416
AIMT Nestlé 174% $2.6B 8/20 #msg-157987026
TCXK.PA SGMO 174% $84M 7/18 #msg-142384127
THOR SNY 172% $2.4B 12/19 #msg-152685325
MGRM LH 171% $155M 6/09 #msg-38960958
NEU.ST AMGN 169% $167M 5/19 #msg-148961436
COLY PFE 167% $165M 11/07 #msg-24600805
INHX BMY 163% $2.5B 1/12 #msg-70636307
LABP ABBV 161% $138M 3/24 #msg-174106073
CYPB Ramius 160% $255M 12/10 #msg-57780859
VTAE AGN 159% $639M 9/16 #msg-125144641
NTMD Deerfld z158% z$36M 1/09 #msg-35132470
CELL BRKR 150% $108M 8/23 #msg-172624283
ICGN PFE 150% $56M 7/11 #msg-65365128
EYE ABT 149% $2.8B 1/09 #msg-34762429
IOMI Intercell 147% $190M 5/08 #msg-29232165
DNL.L NBIX 144% $56.5M 8/22 #msg-169825867
STML Menarini 142% $623M 5/20 #msg-155412863
CPEX FCB_Hldgs 142% $77M 3/11 #msg-61326856
SCTL CoreRx 129% $139M 2/24 #msg-173944768
GEVA ALXN 136% $8.4B 5/15 #msg-113395760
BTRX Stiefel 136% $150M 6/08 #msg-30201906
LMNL Strc Alph 135% $10M 7/23 #msg-172324343
PAND MRK 134% $1.85B 2/21 #msg-162128146
ISTA Bausch&Lm 134% $500M 3/12 #msg-73708628
PTLA ALXN 132% $1.2B 5/20 #msg-155434665
SOMX PTX 127% $25M 12/12 #msg-82334111
Tepnel GPRO 126% $132M 1/09 #msg-35221710
INSV Sun_Phrma 125% $48M 9/15 #msg-116997898
ABLX SNY 123% $4.8B 1/18 #msg-138081925
TPTX BMY 122% $4.1B 6/22 #msg-169044829
ONCE Roche 122% $4.3B 2/19 #msg-147078413
CINC AZN 121% $1.3B 1/22 #msg-170897861
CYNA Sunovion 121% $624M 8/16 #msg-124897051
TTHI OPK 121% $60M 6/16 #msg-123621440
ADLR CBST 121% $190M 10/11 #msg-68264754
SGXP LLY 119% $64M 7/08 #msg-30547648
MDVN PFE k118% $4.0B 8/16 #msg-124680992
HARP MRK 118% $680M 1/24 #msg-173581189
ENCY PFE 118% $350M 2/08 #msg-26978155
CCXI AMGN 116% $3.7B 8/22 #msg-169584273
RARX UCB.BR 112% $2.1B 10/19 #msg-151624039
OPNT INDV.L 111% $110M 11/22 #msg-170443638
HZD.L PKI 110% $368M 11/20 #msg-159255066
BOLD ALPMY 110% $3.0B 12/19 #msg-152574418
IMMU GILD 108% $21B 9/20 #msg-158261866
ICEL Fujifilm 108% $307M 3/15 #msg-112226224
AMYT Chiesi 107% $1.25B 1/23 #msg-170892902
IMGO MRK 107% $1.4B 11/22 #msg-170504136
ARQL MRK 107% $2.7B 12/19 #msg-152684415
AMAM JNJ 105% $2.0B 1/24 #msg-173581189
RYZB BMY 105% $3.6B 12/23 #msg-173501393
TRCA IPN.PA 104% $660M 6/08 #msg-29795183
BLU GSK 103% $2.0B 4/23 #msg-171710496
GBT PFE 102% $5.4B 8/22 #msg-169612752
MRV.TO Srchlight 101% $91M 12/22
AMLN BMY 101% u$7.0B 6/12 #msg-77122453
ARNA PFE 100% $6.7B 12/21 #msg-167099213
TST.TO PLI.TO 100% $33M 8/16 #msg-124735566
HGSI GSK 99% $3.0B 7/12 #msg-77532608
FUSN AZN 97% $2.1B 3/24 #msg-174067117
ORTX KYKOY 97% $387M 19/23 #msg-172963268
CRY.TO MDT 97% $380M 9/08 #msg-32421462
CFMS restor3D 96% $18M 6/23 #msg-172198000
UROV Sumitovant 96% $681M 11/20 #msg-159462428
FTSV GILD 96% $4.9B 3/20 #msg-154105690
NVDQ SYK 96% $701M 6/17 #msg-132304937
IMGN ABBV 95% $10B 11/23 #msg-173325886
CHMA AMYT 94% $330M 5/21 #msg-163605477
BITI ACOR 94% $363M 1/16 #msg-119923883
Speedel NVS 94% $880M 7/08 #msg-30588524
HTWR MDT 93% $1.1B 6/16 #msg-123551339
MEDA.ST MYL 92% $9.9B 2/16 #msg-120456111
MNT JNJ 92% $1.1B 11/08 #msg-33879830
JUNO CELG j91% $9.0B 1/18 #msg-137859642
OCAT Astellas 91% $379M 11/15 #msg-118374922
GI BSX 90% $210M 9/16 #msg-125422608
MEDX BMY 90% $2.1B 7/09 #msg-39801273
CTIC SOBI.ST 89% $1.7B 5/23 #msg-171878780
VRUS GILD 89% $11B 11/11 #msg-69211700
AVXS NVS 88% $8.7B 4/18 #msg-139888382
AGN ACT q88% $66B 11/14 #msg-108238424
OMTH AZN 88% $260M 5/13 #msg-88349427
PNT LLY 87% $1.4B 10/23 #msg-172949338
MAKO SYK 86% $1.65B 9/13 #msg-92358712
ISO BLI 85% $58M 12/22 #msg-170759670
SIRT GSK 85% $620M 4/08 #msg-28705020
ALBO IPN.PA 84% $950M 1/22 #msg-170897349
LJPC INVA 84% $148M 7/22 #msg-169366685
ALDR LUND.CO 84% $1.95B 9/19 #msg-151154641
ZGEN BMY 84% $885M 9/10 #msg-54152162
AMBI Daiichi 83% $315M 9/14 #msg-106688411
ICPT Alfasigma 82% $870M 9/23 #msg-172898719
TRIV ELGX 81% $211M 10/15 #msg-118008485
YMI GILD 81% $510M 12/12 #msg-82377008
NGM Column Gp 80% $135M 2/24 #msg-173922864
DRNA NVO 80% $3.3B 11/21 #msg-166818260
PRVL LLY 80% $880M 12/20 #msg-160184274
TIG TAK 80% $622M 1/18 #msg-137517859
FSTX Sino BPhrm 79% $161M 6/22 #msg-169222236
BHVN PFE 79% $11.6B 5/22 #msg-168806558
KDMN SNY 79% $1.9B 9/21 #msg-165815381
FPRX AMGN 79% $1.9B 3/21 #msg-162316864
CVRS SHL.DE 79% $1.1B 8/19 #msg-151997721
CASC SGEN 79% $614M 1/18 #msg-138145273
AKUS LLY 78% $497M 10/22 #msg-170225029
NTGN BNTX 77% $67M 1/20 #msg-153334198
ACHN ALXN 77% $700M 10/19 #msg-151730899
ATLN.VX JNJ f77% $30B 1/17 #msg-128155201
ORIDN.SW COV 77% $300M 4/12 #msg-74079493
ADMS SUPN 76% $400M 10/21 #msg-166306594
CVTX GILD 76% $1.4B 3/09 #msg-36225695
DCPH Ono Pharma 75% $2.4B 4/24 #msg-174321509
RXDX MRK 75% $10.8B 4/23 #msg-171696785
ARIA TAK 75% $5.2B 1/17 #msg-127718101
OLK TMO 74% $3.1B 10/23 #msg-173043188
RXDX Roche 74% $1.7B 12/17 #msg-137115144
MOVET.BR SHPG 74% $560M 8/10 #msg-52918245
IDEV ENDP 74% $370M 1/09 #msg-34592416
CERE ABBV f73% $8.7B 12/23 #msg-173374544
CPXX JAZZ 73% $1.5B 5/16 #msg-122995888
LEVP VPHM y73% y$510M 7/08 #msg-30704409
TARG MDCO 72% $42M 1/09 #msg-34774402
Ventana Roche 72% $3.4B 1/08 #msg-30912677
Jerini SHPG 71% $520M 7/08 #msg-30452872
MNTA JNJ 70% $6.5B 8/20 #msg-157719675
WTX.ST ALXN 70% $855M 4/18 #msg-139951584
APNO Cell_Bio 70% $20M 9/09 #msg-43348606
TCRR ADAP 69% $80M 3/23 #msg-171370279
AAH.AX CEPH 69% $207M 2/09 #msg-35956544
JNCE Tang Cptl 68% $99M 3/23 #msg-171548303
CNST MOR 68% $1.7B 6/21 #msg-164153449
NITE BIIB 68% $877M 3/19 #msg-147257363
LOXO LLY 68% $8.0B 1/19 #msg-145917745
ARMO LLY 68% $1.6B 5/18 #msg-140678701
STDY UTHR 68% $216M 4/18 #msg-140410572
DDS.TO PLB.TO 68% $15M 8/11 #msg-66272770
ALPN VRTX 67% $4.9B 4/24 #msg-174214641
KDNY NVS 67% $3.2B 6/23 #msg-172110415
APEN BSX 67% $615M 11/22 #msg-170560661
CMTA IPN.PA 67% $1.31B 2/19 #msg-147078420
ALXA Gp_Ferrer 67% $20M 5/16 #msg-122522140
ZGNX UCB.BR 66% $1.9B 1/22 #msg-167551981
NVET ZTS 66% $85M 4/17 #msg-130461127
DRTX ACT 66% $675M 10/14 #msg-106925472
SPPI ASRT 65% $250M 4/23 #msg-171766836
LPDX LH 65% $83M 9/14 #msg-106598786
OSTE MDT 65% $123M 8/10 #msg-53410183
MDCO NVS 64% $9.0B 11/19 #msg-152458295
FCSC Castle_Crk 64% $63M 9/19 #msg-151108594
BIVV SNY 64% $11.6B 1/18 #msg-137861926
LDRH ZBH 64% $1.0B 6/17 #msg-133419822
TLCR GRFS 64% $3.4B 6/10 #msg-50961841
FACT ABT 64% $450M 3/10 #msg-47606240
Acambis SNY 64% $550M 7/08 #msg-30990498
JAV HSP 64% $141M 4/10 #msg-48881292
MSLI Norgine_BV 63% $249M 5/17 #msg-131262204
GRCL AZN 62% $1.0B 12/23 #msg-173501426
ARRY PFE 62% $11.4B 6/19 #msg-149423883
CBMX NVTA 62% $33M 7/17 #msg-133447160
MOR NVS 61% $2.9B 2/24 #msg-173780339
MYOK BMY 61% $13B 10/20 #msg-158699874
Synthes JNJ 61% $21.5B 4/11 #msg-62473819
SCRX Shionogi 61% $1.4B 9/08 #msg-31859174
APGN PYXS 60% $16M 5/23 #msg-171981599
SHPG TAK 60% $62.1B 5/18 #msg-140610505
XNPT Arbor_Phrm 60% $487M 5/16 #msg-122847495
BRLI OPK 60% $1.5B 6/15 #msg-114296569
MAPP AGN 60% $958M 1/13 #msg-83696395
BFRM Merz 60% $253M 1/10 #msg-45071380
RETA BIIB 39% $7.3B 7/23 #msg-172456806
RLYP Galenica 59% $1.53B 7/16 #msg-124014245
CXS.AX CEPH 59% $163M 3/11 #msg-61453144
CRXL JNJ 58% $2.4B 12/10 #msg-55228522
PFNX LGND 57% $438M 8/20 #msg-157515236
VOLC PHG 57% $1.0B 12/14 #msg-109142343
MEDS XON 57% $26M 12/13 #msg-95175483
AVDR GKOS 56% $480M 8/19 #msg-150387068
OMPI VRX 56% $360M 3/13 #msg-86381607
BMTI WMGI 56% $380M 12/12 #msg-81626598
MTXX HIG_Captl 56% $75M 12/10 #msg-57778844
ASPM COV 56% $210M 9/09 #msg-43348479
ANAC PFE 55% $5.2B 5/16 #msg-122659881
RNA BMRN 55% $840M 11/14 #msg-108456369
AUXL ENDP 55% $2.6B 10/14 #msg-107031514
OSIP Astellas 55% $4.0B 5/10 #msg-50234451
IDMI TAK 55% $75M 5/09 #msg-37898204
COLL BDSI 54% $604M 2/22 #msg-167875055
VEC.L PM 54% $1.5B 8/21 #msg-165430280
CELG BMY 54% $74B 1/19 #msg-145844551
ECYT NVS 54% $2.1B 10/18 #msg-144295734
CPHD DHR 54% $4.0B 9/16 #msg-124976329
GNOM BGI-Shnzhn 54% $118M 9/12 #msg-79636464
RDEA AZN 54% $1.3B 4/12 #msg-74706626
BSMD MMSI 54% $96M 5/10 #msg-50161877
ATSI MDT 54% $370M 4/10 #msg-49617936
ALO KG 54% $1.6B 11/08 #msg-33763449
ABGX AMGN 54% $2.2B 12/05 #msg-8876857
KRTX BMY 53% $14B 12/23 #msg-173484423
EPZM IPN.PA 53% $247M 6/22 #msg-169252695
VIE HZNP 53% $2.67B 2/21 #msg-161376573
MEDI AZN 53% $15.2B 4/07 #msg-19020387
MLNM TAK 53% $8.8B 4/08 #msg-28365383
AMRI Crlyl/GTCR 52% $922M 6/17 #msg-131937504
AFFX TMO 52% $1.3B 1/16 #msg-119712743
TRBN EBS 52% $97M 8/10 #msg-53271836
SYNO BAX 52% $260M 12/11 #msg-69906294
PCOP LGND 52% $75M 9/08 #msg-32404474
FRLN SYNC.L 51% $28M 11/23 #msg-173279258
ABMD JNJ 51% $17B 11/22 #msg-170339688
VIFN.SW CSL.AX 51% $12B 12/21 #msg-167114255
RPBIF OrbiMed 51% $11.1M 6/16 #msg-126868605
NPSP SHPG 51% $5.2B 1/15 #msg-109811213
CLZR ELOS 51% $65M 9/09 #msg-41293512
OMRI JNJ 51% $465M 11/08 #msg-33762745
IMCL LLY 51% $6.5B 10/08 #msg-32662830
QSAM TLX.AX 50% $33M 2/24 #msg-173807713
CSII ABT 50% $890M 2/23 #msg-171160898
MYOV Sumitomo 50% $2.9B 10/22 #msg-170268877
ETTX INVA 50% $113M 5/22 #msg-168944440
ATRS HALO 50% $960M 4/22 #msg-168533921
ITMR Zoll Mdcl 50% $538M 9/21 #msg-165885593
GWPH JAZZ 50% $6.7B 2/21 #msg-161448011
CORI Gurnet_Pnt 50% $504M 10/18 #msg-144156114
ENTL SYK 50% $662M 12/17 #msg-136714935
PSTX SYK 50% $120M 1/14 #msg-95510779
MYOG GILD 50% $2.5B 10/06 #msg-13712121
MIL Merck_KGaA 50% $7.2B 3/10 #msg-47249493
CRGN CLDX 50% $40M 5/09 #msg-38262967
TNOX DNA 50% $919M 11/06 #msg-14673162
FMTX NVO 49% $1.1B 9/22 #msg-169846707
OCRX MNK 49% $75M 11/17 #msg-135889221
HZNP AMGN 48% $28B 12/22 #msg-170671017
WMGI SYK 48% $5.4B 11/19 #msg-152075660
SURG VRX 48% $166M 9/15 #msg-116690920
ZY DNA 47% $300M 7/22 #msg-169486788
AAAP NVS 47% $3.9B 10/17 #msg-168310103
FLXN PCRX 47% $428M 10/21 #msg-166306397
CBM Permira 47% $2.4B 8/19 #msg-150386649
KIN ELAN 46% $440M 6/21 #msg-164417443
AMAG Covis_Grp 46% $647M 10/20 #msg-158641344
BEC DHR 46% $6.8B 2/11 #msg-59624646
PHRM CELG 46% $2.9B 11/07 #msg-24645394
ALXN AZN 45% $39B 12/20 #msg-160128002
AGN ABBV 45% $65B 6/19 #msg-149577810
ROCM BCR 45% $262M 9/13 #msg-91684202
TYME SYRS 44% $70M 7/22 #msg-169317107
BSTC ENDP 44% $540M 10/20 #msg-158976969
AAAP NVS 44% $3.9B 10/17 #msg-135797034
GNVC XON 44% $14.2M 1/17 #msg-128087921
ICVX AZN 43% $800M 12/23 #msg-173410902
DBTX REGN 43% $109M 8/23 #msg-172552134
VECT IRWD 43% $1.0B 5/23 #msg-171960647
AVEO LG Chem 43% $566M 10/22 #msg-170225142
GNMK Roche 43% $1.8B 3/21 #msg-162557955
SNMX Firmenich 43% $72M 9/18 #msg-143614780
RPRX AGN 43% $27M 12/17 #msg-136820335
DICE LLY 42% $2.4B 6/23 #msg-172170829
SGEN PFE 42% $43B 3/23 #msg-171430587
AGTC SYNC.L 42% $24M 10/22 #msg-170272356
ZSPH AZN 42% $2.7B 11/15 #msg-118292261
ASPX TEVA 42% $3.2B 3/15 #msg-112224762
CALP PKI 42% $600M 9/11 #msg-66915400
BRL TEVA 42% $9.0B 7/08 #msg-30792830
PRTK Gurnet Pt 41% $330M 6/23 #msg-172070130
EIDX BBIO 41% $2.9B 10/20 #msg-158699182
AST BTX 41% $85M 11/18 #msg-144764100
VITA SYK 41% $320M 5/11 #msg-63178312
AGAM STJ 41% $1.3B 10/10 #msg-55673504
MNLO FOMX 40% $180M 11/19 #msg-152208625
DSCI IART 40% $204M 1/17 #msg-127779613
SGNT Nichi-Iko 40% $736M 7/16 #msg-123792475
PATH TEVA 40% s$144M 1/14 #msg-96147237
SLTM VRX 40% $236M 12/13 #msg-95003986
KG PFE 40% $3.6B 10/10 #msg-55425514
STSA Shin Nippn 39% $30M 4/23 #msg-171700091
SRRA GSK 39% $1.9B 4/22 #msg-168533694
PCYC ABBV n39% $21B 3/15 #msg-111425234
SYR.L STE 39% $1.9B 10/14 #msg-107152734
HSP PFE 39% $17B 2/15 #msg-110577169
MRX VRX 39% $2.6B 9/12 #msg-79186818
CEPH TEVA 39% $6.8B 5/11 #msg-62636692
ORCH LH 39% $85M 4/11 #msg-61801828
MOGN Eisai 39% $3.9B 12/07 #msg-25163775
SPNE OFIX 38% $306M 10/22 #msg-170165454
PETX ELAN 38% $231M 4/17 #msg-148466146
ALR ABT 38% $7.9B 4/17 #msg-130492505
BXLT SHPG 38% $32B 1/16 #msg-119743932
ITMN Roche 38% $8.3B 8/14 #msg-105603127
SNTS SLXP 38% $2.6B 11/13 #msg-93839578
ONXX AMGN 38% $9.7B 8/13 #msg-91383118
LIFE TMO 38% $15.6B 4/13 #msg-86836458
DUSA Sun_Pharma 38% $230M 11/12 #msg-81273572
AERI ALC 37% $770M 8/22 #msg-169759599
TTPH LJPC 37% $43M 6/20 #msg-156488296
BTG.L BSX 37% $4.2B 11/18 #msg-145001575
STJ ABT 37% $30.7B 4/16 #msg-122251293
CBST MRK 37% $9.5B 12/14 #msg-108853418
SIAL Merck_KGaA 37% $17B 9/14 #msg-106484466
PRX TPG_(prvt) 37% $1.9B 7/12 #msg-77533202
MTOX LH 37% $240M 6/12 #msg-76240732
GENZ SNY v37% v$20.1B 2/11 #msg-59975091
DOVA SOBI.ST 36% $810M 9/19 #msg-151425501
MRTX BMY 35% $4.8B 10/23 #msg-172983547
SURF CHRS 35% $40M 6/23 #msg-172154287
SOBI.ST Advent/GIC 35% $8.0B 9/21 #msg-165744197
CORV Advance_Ph 35% $76M 3/20 #msg-154356839
PTHN TMO 35% $7.2B 5/17 #msg-131355584
DYAX SHPG 35% $5.9B 11/15 #msg-118164544
MATK Royal_DSM 35% $1.1B 12/10 #msg-57987049
MITO Mrngsd Vnt 34% $27M 8/22 #msg-169552098
NEOS AYTU 34% $45M 12/20 #msg-160066262
WCRX ACT 34% $8.5B 5/13 #msg-88088454
AMMD ENDP 34% $2.9B 4/11 #msg-61948007
CLRT GE 34% $580M 10/10 #msg-55864640
SGP MRK 34% $41B 3/09 #msg-36140327
HTRN ENDP 34% $223M 5/10 #msg-49838813
CLCD LLY 33% $960M 1/17 #msg-127941157
AKGZF Bayer 33% $2.9B 12/13 #msg-95174198
KNSY Royal_DSM 33% $360M 5/12 #msg-75204020
MITI AMGN 33% $1.16B 1/12 #msg-71341339
OYST VTRS 32% $300M 11/22 #msg-170389075
JNP CTLT 32% $140M 7/18 #msg-141961886
CVD LH 32% $5.6B 11/14 #msg-107784169
SMTS COV 32% $250M 6/10 #msg-51344183
EXAC TPG_(prvt) 31% $625M 10/17 #msg-135627315
TOMO ARAY 31% $277M 3/11 #msg-60697854
TBIO SNY 30% $3.2B 8/21 #msg-165242244
PRAH ICLR 30% $12B 2/21 #msg-162100993
NXTM FMS 30% $2.0B 8/17 #msg-133627112
THOR STJ 30% $3.4B 7/15 #msg-115599422
PPD(I) CarlyleGrp 30% $3.9B 10/11 #msg-67625255
OctoPlus RDY 30% $35M 10/12 #msg-80752228
CGPI Galderma 30% $420M 2/08 #msg-28286522
NTUS ArchiMed 29% $1.2B 4/22 #msg-168574161
XLRN MRK 29% $11.5B 9/21 #msg-166156870
IVTY SYK 29% $190M 9/18 #msg-143493139
FMI Roche 29% h$2.4B 6/18 #msg-141630144
COV MDT 29% $42.9B 6/14 #msg-103352775
CHTP Lundbeck 29% $530M 5/14 #msg-101687352
WYE PFE 29% $68B 1/09 #msg-35077617
APPX Fresenius 29% $940M 7/08 #msg-30498388
KITE GILD 29% $11.9B 8/17 #msg-134179317
GTKX.PA CALT 28% $38M 8/20 #msg-157592686
PRXL Pamplona 28% $4.6B 6/17 #msg-132330332
INNL Gurnet_Pt 28% $53M 4/17 #msg-130210863
CYNO HOLX 28% $1.44B 2/17 #msg-128697104
CRA DGX 28% $330M 3/11 #msg-61103240
SEPR Dainippon 28% $2.6B 9/09 #msg-41143301
CBAY GILD 27% $4.3B 2.24 #msg-173827237
NVCN SWAV 27% $199M 1/23 #msg-170962426
OXFD PKI 27% $600M 1/21 #msg-160749373
HEMA CRL 27% $380M 12/19 #msg-152826703
SPNC PHG 27% $2.16B 6/17 #msg-132563070
QCOR MNK 27% $5.6B 4/14 #msg-100144844
CNJ.TO EBS 27% $222M 12/13 #msg-94886880
GIVN COV 27% $860M 12/13 #msg-94759019
VPHM SHPG 27% $4.2B 11/13 #msg-93924184
ASTX Otsuka 27% $886M 9/13 #msg-91706292
ALTH SPPI 27% $108M 4/12 #msg-74081029
GXDX NVS 27% $330M 1/11 #msg-59092015
SOLY ABBV 26% $550M 5/21 #msg-163706786
KTWO SYK 26% $1.4B 8/18 #msg-143281972
LBMH BCR 26% $181M 11/15 #msg-118658269
CFN BD 26% $12.2B 10/14 #msg-106924866
CADX MNK 26% $1.3B 2/14 #msg-97103062
ISPH MRK 26% $430M 4/11 #msg-61724403
Zentiva SNY 26% $2.6B 9/08 #msg-32327005
AMTI CYTH 25% $11M 12/23 #msg-173513038
CEMI ALBIO.PA 25% $17.2M 1/23 #msg-171085285
KARO.ST EQT_VIII 25% $650M 10/18 #msg-144517455
BCR BDX 25% $24B 4/17 #msg-130730335
SLXP VRX p25% $15.9B 3/15 #msg-111768607
FRX ACT 25% $25B 2/14 #msg-97422529
ICOS LLY 25% $2.3B 12/06 #msg-15623908
PPD TMO 24% $20.9B 4/21 #msg-163201848
VAR SHL.DE 24% $16.4B 8/20 #msg-157315433
KYTH AGN 24% $2.1B 6/15 #msg-114667193
HITK AKRX 24% $540M 8/13 #msg-91428592
ZOLL AsahiKasei 24% $2.2B 3/12 #msg-73194976
RCOR RCKT 23% $53M 9/22 #msg-169991990
LMNX DIA.MI 23% $1.8B 4/21 #msg-163126009
ISEE Astellas 22% $5.9B 5/23 #msg-171807035
ALMED.PA MDT 22% $160M 7/20 #msg-156929697
Noven Hisamitsu 22% $428M 7/09 #msg-39515681
RPTP HZNP 21% $800M 9/16 #msg-125097197
DNEX TMO 21% $2.1B 12/10 #msg-57686719
EQRX RVMD 20% $1.1B 8/23 #msg-172491486
PLB.TO ENDP 20% $74M 11/13 #msg-93718507
CPTS Bayer 20% $1.1B 4/13 #msg-87353545
PBTH OPK 20% $480M 4/13 #msg-87185863
GPRO HOLX 20% $3.7B 4/12 #msg-74999864
FURX FRX 19% $1.1B 4/14 #msg-101191792
CLDA FRX 19% $1.2B 2/11 #msg-60171753
PPCO ENDP 19% $168M 8/10 #msg-53137069
EVVV COV 19% $2.6B 6/10 #msg-50797343
RCPT CELG 18% $7.2B 7/15 #msg-115406201
SWAV JNJ 17% $12.5B 4/24 #msg-174182514
CTLT NVO Hldngs 17% $11.5B 2/24 #msg-173773953
RAIN Pathos AI 17% c.v. 12/23 #msg-173423820
PRDS MediPac 17% c.v. 7/23 #msg-172362079
MSON BVS 17% $518M 7/21 #msg-166521465
BEAT PHG 17% $2.8B 12/20 #msg-160299656
NDRM Mitsubishi 17% $1.1B 7/17 #msg-133239153
KCI Apax_Prts 17% $6.3B 7/11 #msg-65162696
ABII CELG 17% $2.9B 6/10 #msg-51844360
ACL NVS x17% x$49.7B 1/10 #msg-45072999
CNCE Sun Pharma 16% $580M 1/23 #msg-170981214
MZOR MDT 16% $1.64B 9/18 #msg-143696059
VER.L LGND 16% $43M 8/18 #msg-142795933
ABAX ZTS 16% $2.0B 5/18 #msg-140837816
AEGR QLTI m16% $45M 6/16 #msg-123312384
KMNS XIO_Grp 16% $510M 6/15 #msg-114711266
PRXN.L Upshr-Smth 16% $350M 6/12 #msg-76556065
CGRB JNJ 16% $970M 5/09 #msg-38039851
DNA Roche 16% w$46.8B 3/09 #msg-36224175
XENT MDT 15% $1.1B 8/21 #msg-165323285
SCMP MNK 15% $1.2B 12/17 #msg-137177653
TSRX CBST 15% $707M 7/13 #msg-90492857
ARI.TO Roche 15% $190M 7/08 #msg-30904056
EMIS NVO 14% $1.8B 11/20 #msg-159336565
ZLTQ AGN 14% $2.48B 2/17 #msg-128649430
FEIC TMO 14% $4.2B 5/16 #msg-122953139
SENO BCR 14% $213M 5/10 #msg-49838776
SBBP XERS 13% $267M 5/21 #msg-163992064
PGNX LNTH 13% $440M 2/20 #msg-153933488
AVNR Otsuka 13% $3.5B 12/14 #msg-108677894
RDUS Gurnet Pt 12% $890M 6/22 #msg-169222128
SCLN GL_Capital 11% $605M 6/17 #msg-132004673
WX prvt_grp 11% $3.3B 8/15 #msg-116208102
ELN PRGO 11% $6.7B 7/13 #msg-90418077
PRNB SNY 10% $3.36B 8/20 #msg-157669162
TGX Juniper 9% $52M 8/13 #msg-90677660
EURX Axcan 9% $583M 12/10 #msg-57543845
KNTE XOMA 8% $120M 2/24 #msg-173861156
HPTX HZNP 8% $1.1B 3/15 #msg-112225598
PMTI CYNO 8% $294M 3/13 #msg-85810217
TWTI HOLX 7% $580M 6/08 #msg-29877950
ARTC SN.L 6% $1.7B 2/14 #msg-96750072
CEGE BPAX 6% $38M 6/09 #msg-39163410
MEND JNJ 6% $480M 7/10 #msg-52176337
THRX Tang Cptl 5% c.v. 12/23 #msg-173484642
GHDX EXAS 5% $2.8B 7/19 #msg-150192700
ELOS Apax_Prtns 4% $397M 4/17 #msg-130128751
PRON.OL BASF 4% $844M 12/12 #msg-81711876
ABCM DHR 3% $5.7B 8/23 #msg-172703284
DERM LLY 2% $1.1B 1/20 #msg-153222680
GENT JAZZ 2% $1.0B 12/13 #msg-95143526
OSIR SNN 1% $660M 3/19 #msg-147467838
RLM EPIX (3%) $22M 5/19 #msg-148855792
CRTX Chiesi (3%) t$106M 9/13 #msg-92046498
VXGN OXGN (4%) $33M 10/09 #msg-42578130
AVGN MNOV (7%) $38M 8/09 #msg-40769841
VRX BVF (7%) $3.9B 6/10 #msg-51505172
VELO.CO Asahi (9%) $1.3B 11/19 #msg-153256195
GNMX CERC (11%) $16M 12/19 #msg-152639293
KERX AKBA (13%) $475M 6/18 #msg-141859230
OPTR CBST (19%) $535M 7/13 #msg-90492857
ACPH.BR EGRX (30%) $104M 3/22 #msg-168352276
DPLO UNH (31%) $300M 12/19 #msg-152689666
MRLB SIEN (78%) $20M 6/17 #msg-132114929
TLON SPPI ‡(85%) ‡$11M 7/13 #msg-90020541
RPHM OKUR ® ® 5/24 #msg-174406669
KTRA HURA ® ® 4/24 #msg-174166810
ABIO ORCA ® ® 4/24 #msg-174165127
ONTX TRAW ® ® 4/24 #msg-174158771
AVRO TECX ® ® 1/24 #msg-173735605
FIXX QTTB ® ® 11/13 #msg-173237730
GRPH LENZ ® ® 11/23 #msg-173227879
SELB RNAC ® ® 11/23 #msg-173210464
INVO NAYA ® ® 10/23 #msg-173075987
ADXS Biosight ® ® 7/23 #msg-172456806
NLTX NGNE ® ® 7/23 #msg-172374206
FREQ KRRO ® ® 7/23 #msg-172338919
TALS TRML ® ® 6/23 #msg-172187751
IMNM Morphimmune ® ® 6/23 #msg-172242569
NANOV.OL Thor Med ® ® 6/23 #msg-172098515
MGTA DNTH ® ® 5/23 #msg-171829261
DFFN CRVO ® ® 3/23 #msg-171578139
ADMP DMK Pharma ® ® 2/23 #msg-171314445
VBLT NTBL ® ® 2/23 #msg-171281477
ANGN ELTX ® ® 1/23 #msg-170962134
VLON GRI ® ® 12/22 #msg-170687186
GRAY CALC ® ® 11/22 #msg-170512654
ADXS Ayala ®g ® 10/22 #msg-170233693
IMRA ELVN ® ® 10/22 #msg-170192000
RMED VTAK ® ® 9/22 #msg-170581567
SESN CARM ® ® 9/22 #msg-170005327
GMTX IRON ® ® 8/22 #msg-169638662
SBTX SPRY ® ® 7/22 #msg-169465202
YMTX KA ® ® 6/22 #msg-169066703
CLBS LSTA ® ® 4/22 #msg-168674675
EYES VANI ® ® 2/22 #msg-167798986
POLN.SW SPEX.SW ® ® 12/21 #msg-167295474
AZRX FWBI ® ® 9/21 #msg-165885811
EARS CYTO ® ® 6/21 #msg-164184643
ARPO AADI ® ® 5/21 #msg-163841604
MLND TPST ® ® 3/21 #msg-162851398
APOP Quoin_Phrm ® ® 3/21 #msg-162798374
NTEC INDP ® ® 3/21 #msg-162565942
OBLN RSLS ® ® 1/21 #msg-161068114
NK IBRX ® ® 12/20 #msg-160358069
SNCA PALI ® ® 12/20 #msg-160265342
ANCN CMMB ® ® 12/20 #msg-160187408
SNSS VIRX ® ® 11/20 #msg-159786611
AKER MYMD ® ® 11/20 #msg-159445834
CBLI STAB ® ® 10/20 #msg-158993566
PTI YMTX ® ® 8/20 #msg-157833849
CGIX VYNT ® ® 8/20 #msg-157834952
ARYBU CERE ® ® 7/20 #msg-157265361
SBPH FSTX ® ® 7/20 #msg-157245800
UMRX Kiq_LLC ® ® 7/20 #msg-156717827
REXN OCUP ® ® 6/20 #msg-156362145
ADRO KDNY ® ® 6/20 #msg-155991705
NTRP PTPI ® ® 5/20 #msg-155701445
TORC ACET ® ® 4/20 #msg-155341382
ARYA IMTX ® ® 3/20 #msg-155937184
TOCA FBRX ® ® 2/20 #msg-153935298
BPMX TMBR ® ® 1/20 #msg-153535078
CNAT HSTO ® ® 1/20 #msg-153532517
RTTR QLGN ® ® 1/20 #msg-153405835
ZFGN LRMR ® ® 12/19 #msg-152862497
NLNK LUMP ® ® 9/19 #msg-151442042
PRTO TARA ® ® 9/19 #msg-151308631
OPGN CURE.AS ® ® 9/19 #msg-150924660
AQXP NLTX ® ® 8/19 #msg-150347293
GEMP NRBO ® ® 7/19 #msg-150120289
MYND EMMA ® ® 7/19 #msg-150069355
CHAC PHGE ® ® 7/19 #msg-150003368
VICL BBI ® ® 6/19 #msg-149171531
ALQA ADYX ® ® 4/19 #msg-148356921
MATN OTLC ® ® 4/19 #msg-148312861
HSGX OCGN ® ® 4/19 #msg-148102776
VTL IMUX ® ® 4/19 #msg-148027472
SBOT EDSA ® ® 3/19 #msg-147384278
GTXI ONCT ® ® 3/19 #msg-147349916
FLKS SLRX ® ® 1/19 #msg-145871960
APHB ARMP ® ® 1/19 #msg-145870884
OHRP NBSE ® ® 1/19 #msg-145848413
OMED MREO ® ® 12/18 #msg-145273044
ASNS XFOR ® ® 11/18 #msg-145105702
EDGE PDSB ® ® 11/18 #msg-145087200
ORPN ENLV ® ® 11/18 #msg-144993741
OVAS MLND ® ® 8/18 #msg-142796422
APRI SEEL ® ® 7/18 #msg-142554689
TPIV MRKR ® ® 6/18 #msg-141234250
VSAR ARAV ® ® 6/18 #msg-141288246
PSDV EYPT ® ® 4/18 #msg-139636450
DDRT ENOB ® ® 2/18 #msg-155616042
SVON ELOX ® ® 12/17 #msg-137129259
AVIR VXRT ® ® 10/17 #msg-135798068
NEOT EVFM ® ® 10/17 #msg-135475699
IPXL AMRX ® ® 10/17 #msg-135476435
HUWX PCSA ® ® 10/17 #msg-135169711
ADHD ARCT ® ® 9/17 #msg-134959115
ITEK RCKT ® ® 9/17 #msg-134563146
OXIS GTBP ® ® 8/17 #msg-133992461
CEMP MLNT ® ® 8/17 #msg-133699889
GALE SLS ® ® 8/17 #msg-133668985
AEPP ONCX ® ® 8/17 #msg-133655781
MDSI INNT ® ® 7/17 #msg-138124228
OPXA ACER ® ® 7/17 #msg-132682989
MIRN SYBX ® ® 5/17 #msg-131394212
NVLS ALPN ® ® 4/17 #msg-130583796
CERU DARE ® ® 3/17 #msg-129681349
THLD MTEM ® ® 3/17 #msg-129612892
JAGX Napo_Pharma ® ® 2/17 #msg-133472369
PIP ALT ® ® 1/17 #msg-127979048
MSTX SVRA ® ® 1/17 #msg-127699319
OGXI ACHV ® ® 1/17 #msg-127671152
GTCL.PA GKTX.PA ® ® 12/16 #msg-127378262
DPRX PLXP ® ® 12/16 #msg-127377082
TKAI OTIC ® ® 12/16 #msg-127360808
COOL PTE ® ® 12/16 #msg-127170327
MRNA IthenaPhrma ® ® 11/16 #msg-126593922
SGNL MGEN ® ® 11/16 #msg-126214730
TBIO PRPO ® ® 10/16 #msg-125767889
EBIO Viventia ® ® 9/16 #msg-125325110
LPTN APEN ® ® 9/16 #msg-125044826
MCUR LPTX ® ® 8/16 #msg-124830007
STEM MBOT ® ® 8/16 #msg-124542946
CBYL KALV ® ® 6/16 #msg-123315137
AAVL Annapurna ® ® 5/16 #msg-122582472
BIOD ALBO ® ® 5/16 #msg-122880969
SNTA MDGL ® ® 4/16 #msg-121919321
APPY Strand_LS ® ® 1/16 #msg-120095130
RESX DFFN ® ® 1/16 #msg-119714298
CLDN EIGR ® ® 11/15 #msg-118623913
VBI SVACF ® ® 10/15 #msg-120043416
CLTX Volution ® ® 7/15 #msg-115354702
RTGN PULM ® ® 6/15 #msg-114559267
TBUFF POZN ® ® 6/15 #msg-114404029
DARA MTPH.L ® ® 6/15 #msg-114299115
TRGT CBIO ® ® 3/15 #msg-111461780
RGDO TBRA ® ® 1/15 #msg-109912303
TKMR ABUS ® ® 1/15 #msg-109820030
TSPT PRTK ® ® 7/14 #msg-103895855
VTUS ASMB ® ® 5/14 PR link
TELK MBVX ® ® 5/14 #msg-101987443
ZLCS EPRS ® ® 4/14 #msg-100707725
NABI Biota ® ® 11/12 #msg-81312718
TRMS GEVA ® ® 6/11 #msg-64249161
VSGN IPC ® ® 8/09 #msg-40603745
PGLA Avexa ® ® 12/08 #msg-34341452
NUVO ABIO ® ® 9/08 #msg-32420015
NOVC TSPT ® ® 9/08 #msg-31869987
SNUS OGXI ® ® 5/08 #msg-29604972

‡ Relative to “unaffected” share price in cases where
a buyout offer or auction was made public; excludes
CVRs unless otherwise specified.

* Adjusted for cash/debt on acquired company’s balance
sheet; excludes CVRs unless otherwise specified.

® Reverse merger; premium not calculable.

c.v. No premium to cash value of acquired company.

f Premium relative to “unaffected” closing price on 12/1/23

g Merged co named Ayala but trades under ADXS symbol.

h For 43% of company not already owned.

j Relative to “unaffected” closing price on 1/16/18.

k Premium relative to 3/30/16 close.

m Merged company to be named Novelion.

n Premium relative to 2/24/15 (before leak of buyout bidding war).

p Premium relative to 8/18/14 (before speculation re AGN takeover).

q Premium relative to 4/10/14 (before Pershing Sq accumulation). After the merger, Actavis (ACT) renamed itself Allergan (AGN).

s Premium excludes contingent fees and is calculated from
12/13/13 close, the day before ENDP offer.

t For 42% of company not already owned.

u Includes $1.7B assumption of debt; premium relative to
3/27/12 close, when Bloomberg reported BMY bid. AZN pays
BMY $3.4B to put AMLN’s portfolio into 50/50 JV.

v Excluding CVR of $4-14/sh; premium relative to 7/22/10 close.

w For 44% of DNA not already owned.

x Price includes entire deal in three stages; 17% premium is the
blended avg price of NVS’ purchases ($164) relative to ACL’s market
price 4/4/08 immediately prior to announcement of first stage of deal.

y Includes $0.45/sh of contingent payments.

z Liquidated by Deerfield following failed merger with Archemix.

DewDiligence PremiumMember

05/13/24 12:31 PM

Post #251,802

Re: #250,076: @DewDiligence - RPHM -87% on phase-3 failure—70% workforce reduction:

RPHM reverse-merges with—(private)—OnKure:

https://finance.yahoo.com/news/reneo-pharmaceuticals-onkure-announce-proposed-113500103.html

The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3K-alpha), including its lead program OKI-219, which is currently in a Phase 1 clinical trial for the treatment of solid tumors. Upon completion of the transaction, the combined company is expected to operate under the name OnKure Therapeutics, Inc., and trade on the Nasdaq Global Market under the ticker symbol “OKUR”.

… Pre-merger Reneo stockholders are expected to own approximately 31% of the combined company, and pre-merger OnKure stockholders are expected to own approximately 69% of the combined company, upon the closing of the merger, exclusive of the PIPE financing.

RPHM has essentially been a shell company since its phase-3 failure and workforce reduction in Dec 2023 (#msg-173427205).

DewDiligence PremiumMember

05/13/24 11:20 AM

Post #251,801

Re: #242,833: @DewDiligence - ACIU/Roche—Crenezumab fails phase-2 trial in early-onset AD:

ACIU—(+35%)—inks Takeda collaboration for anti-amyloid immunotherapy for AD—$100M up-front cash:

https://finance.yahoo.com/news/ac-immune-takeda-sign-exclusive-100000575.html

floblu14

05/13/24 8:27 AM

Post #251,800

Collegium Announces $35 Million Accelerated Share Repurchase Program
May 13, 2024

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.

“Our financial and strategic execution bolster the strength of our business today and in the future. Collegium’s strong start to 2024 was supported by robust cash generation, momentum in Belbuca® prescriptions, improved Xtampza® ER gross-to-net and the Nucynta Franchise authorized generic agreement, all of which put us on track to meet our 2024 financial guidance and improve our outlook in 2025 and beyond,” said Colleen Tupper, Chief Financial Officer of Collegium. “This $35 million ASR program reinforces our belief that the value of Collegium is underappreciated. We remain committed to leveraging our $150 million share repurchase program, which is authorized through the second quarter of 2025, to create value for our shareholders through our capital deployment strategy.”

Under terms of the agreement, Collegium will pay $35 million to Jefferies LLC and will receive an initial delivery of 888,889 shares, based on the $31.50 closing stock price of Collegium’s common stock on May 10, 2024, representing approximately 80% of the total shares the Company expects to repurchase under the ASR agreement. The final number of shares repurchased will be based on the volume-weighted average prices of Collegium’s common stock during the term of the ASR and subject to adjustments related to the terms and conditions of the ASR agreement. The final settlement of the ASR is expected to be completed in the third quarter of 2024. As of March 31, 2024, Collegium had approximately 32.7 million shares outstanding.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-35-million-accelerated-share-repurchase

vinmantoo

05/12/24 1:17 PM

Post #251,799

Re: #251,798: @jbog - Note: I am deeply underwatered here so ...

I lost my shirt and sold out at 10 which was very very unusual for me. I hate to lose so I normally let the stock sit in my accounts and then gradually add to them on a quarterly basis.

I have been shuffling my RVNC to generate tax losses and have increased shares in the interval and am sitting at a 50% loss. I am fine waiting to see what happens, but will likely do a little more turning over for tax purposes and then adding back.

A couple of years ago I bought some Tril (5K) for $0.50 and then it dropped considerably, I then spent a year adding. My last buy was at $0.17. And 11 months later sold 70k shares for $1.4 mil,

Currently have a ton of Iova where my last buy was at $3.75 6 months ago which now is $11. RGLS went from 50cents to $2,50 in 5 months.

jbog, Kudos for your big score on TRIL. I did quite well with TRIL too. You have mentioned RGLS several times and I asked why you are so high on it but you haven't responded. Could you clue me and the board into why?

jbog

05/11/24 8:51 PM

Post #251,798

Re: #251,797: @alertmeipp - Yeah, they need about 21% per quarter to

Note: I am deeply underwatered here so ...

I lost my shirt and sold out at 10 which was very very unusual for me. I hate to lose so I normally let the stock sit in my accounts and then gradually add to them on a quarterly basis. A couple of years ago I bought some Tril (5K) for $0.50 and then it dropped considerably, I then spent a year adding. My last buy was at $0.17. And 11 months later sold 70k shares for $1.4 mil,

Currently have a ton of Iova where my last buy was at $3.75 6 months ago which now is $11. RGLS went from 50cents to $2,50 in 5 months.

If you believe in it put it away and add when you can.

Good luck

alertmeipp Free

05/11/24 7:49 PM

Post #251,797

Re: #251,796: @WorstLuck - For Revance to hit it's 2024 projection they'll

Yeah, they need about 21% per quarter to hit the 280mm guidance if we assume linear growth.

Last year, RHA revenue was 128mm, if we assume 15% yoy growth, RHA will around 147mm, leaving 133mm gap for Daxxify to fill.

Last year Daxxify sales was 84mm, they will need 60% YoY growth to get to 133mm sales. Just for discussion sake, that's 30% in next 3 quarters.

>> Do you see that happening?

Yes, I think it's do-able but I am obviously biased here. The key here is whether Launch 2.0 will have similar momentum as the initial launch. Last year, the Daxxify growth rate was 45% Q2 vs Q1 - so 30% is not a wildest dream.

Note: I am deeply underwatered here so ...

WorstLuck

05/11/24 3:34 PM

Post #251,796

Re: #251,793: @jbog - alertmeipp, For Revance to hit it's 2024 projection they'll

For Revance to hit it's 2024 projection they'll have to increase sales >24% in each of final three quarters

Do you see that happening? Hopefully, but that's a stretch.

We'll have to see what RHA-3 sales do to total RHA sales in Q2 to have a better idea. Playing with the numbers and some assumptions, RHA has to do some pretty heavy lifting even with optimistic Daxxy numbers. I have no idea what numbers to expect from the RHA-3 addition for the whole RHA collection so I'll just wait for Q2 results.

DewDiligence PremiumMember

05/11/24 2:54 PM

Post #251,795

Re: #251,793: @jbog - alertmeipp, For Revance to hit it's 2024 projection they'll

I've never heard a company say we report $20mil in sales but they were actually $22mil but someone used coupons? That's laughable.

Not at all—it's standard GAAP accounting of “net revenue.” Under GAAP, a coupon applied at the time of service must be treated as an offset to revenue (rather than as a marketing expense).

DewDiligence PremiumMember

05/11/24 2:46 PM

Post #251,794

Re: #251,789: @oc631 - SNY must believe either that the NVAX platform

NVAX—They filed their 10-Q and the 8-K for their earnings release yet what's notably absent is the 8-K announcing the SNY deal…

The SNY deal is discussed at length in the 10-Q. Edit: I noticed that you menitoned this in a subsequent post.

Anyone think there will be a follow-on offering on Monday?

Possible but unlikely, IMO. The $569M of cash received from SNY (including $69M from SNY’s purchase of 6.9M NVAX shares @$10.00) should provide ample liquidity.

jbog

05/11/24 2:03 PM

Post #251,793

Re: #251,792: @alertmeipp - I think the market is in general very

alertmeipp,

For Revance to hit it's 2024 projection they'll have to increase sales >24% in each of final three quarters

Do you see that happening? Hopefully, but that's a stretch.

I've never heard a company say we report $20mil in sales but they were actually $22mil but someone used coupons? What. That's laughable.

alertmeipp Free

05/11/24 12:55 PM

Post #251,792

Re: #251,786: @WorstLuck - at this point it's clear Foley has

I think the market is in general very pessimistic and skeptic toward RVNC

Seems not many believe they can hit this years guidance and become cash flow positive next year

Need a few quarters of executions to turn the tide

But overall I think this will start to trade better into the Summer just because I expect most non believers would be out by now

xavierprivas Free

05/11/24 10:26 AM

Post #251,791

Re: #251,790: @oc631 - I suspect some developers, more specifically protein-based vaccine

I had my Covid shot back in October '23 so when NVAX Covid vaccine came out in February I recommended to 2 friends of mine, one
lives in Atlanta the other one in Dallas. Well they got their NVAX Covid shot with difficulty, both of them got it at Costco.

I want to get another Covid shot before I start traveling this June so I check all the 4 pharmacies in Atlanta that NVAX claims having
their products. None of them has it. Just an anecdotal evidence on NVAX distribution or marketing strategy.

oc631

05/11/24 5:03 AM

Post #251,790

Re: #251,694: @oc631 - I don't want you further upsetting NVAX investors

I suspect some developers, more specifically protein-based vaccine developers, are frontrunning this decision and are already manufacturing JN.1 COVID vaccine to give the appearance they are competitive in development time and scalability yet if there was another pandemic it would become clear they are not due to time constraints.

I need to walk back this statement. NVAX is applying for EUA and a BLA using prefilled syringes this season. A decision made to remain competitive but in turn creating uncertainty and additional risk. A small company building up a large inventory of PFS product before being granted market authorization would seem inadvisable. Yes MRNA moved to a PFS product by why not PFE? It may have more to do with fill/finish requirements than cost. Granting EUA during a controlled COVID endemic will come with much higher requirements and standards than years past. Furthermore NVAX has signed APA's with Australia and Canada so things could get messy if the company runs into delays.

The terms of the deal were added into the same day 10-Q release so perhaps the company felt this would be a redundancy. Normally NVAX wouldn't be so efficient but they needed a valid reason to remove the "going concern" disclosure.

oc631

05/11/24 1:55 AM

Post #251,789

Re: #251,784: @dewophile - $500M up-front cash

SNY must believe either that the NVAX platform can enable you to pick a flu strain on VERY short notice

Most seasons we can expect a standard endemic covid and flu market with sufficient lead time to produce a protein-based option. SNY adds scalability and manufacturing that NVAX needed almost as much as they need cash. Yet the days of wallowing over picking the wrong seasonal strain are probably over with mRNA vaccines. Developers can change on a dime and offer a late-season alternative if needed. I'm convinced we are no longer wedded to annual decisions even though current guidance seems to suggest this. If a VOC strain were to emerge late this season it would have put NVAX out of business and now they are backstopped.

Just an observation on NVAX. They filed their 10-Q and the 8-K for their earnings release yet what's notably absent is the 8-K announcing the SNY deal (as of the time of this post). Anyone care to guess why? Anyone think there will be a follow-on offering on Monday?

Biowatch

05/10/24 9:36 PM

Post #251,788

Re: #251,784: @dewophile - $500M up-front cash

pick a flu strain on VERY short notice

could be an important tool to stop the spread in a confined setting like a ship or a hospital or university, etc.

These days, genome sequencing is fast and efficient, which is part of the equation.

No need to guess what strains are likely to be prevalent a year in advance, the current approach to producing flu vaccines that is hit or miss at best.

There are stories about bird flu showing up in cow’s milk which has farmers concerned. If the milk is pasteurized, the virus is destroyed, but at least one farm worker was infected.

So, although the sky is not falling, chicken little, the ability to recognize new strains and produce a vaccine quickly, even if in small quantities, is a definite plus.

DewDiligence PremiumMember

05/10/24 5:02 PM

Post #251,787

Re: #250,628: @DewDiligence - MACK seeks shareholder approval to dissolve—with liquidating dividend

MACK shareholders approve dissolution—cash distribution=$15.10/sh:

https://www.businesswire.com/news/home/20240510857372/en

The liquidating distribution stems from a $225M milestone payment MACK received from Ipsen for FDA approval of Onivyde (#msg-173845049).

MACK had been a shell company with a contingent receivable since ceasing operations almost five years ago (#msg-149704592).

WorstLuck

05/10/24 1:21 PM

Post #251,786

Re: #251,785: @iwfal - Seeing the right kind of progress at least

at this point it's clear Foley has zero idea how to manage (eg ALWAYS reactive, and even then in a vague short term way) and the adults are waiting way too late to make a change.

Sure, but the same thing could have been said (and was said) years ago. You deal with the realities you have, and that means waiting for something good to happen before getting too excited about the prospects.

iwfal

05/10/24 12:42 PM

Post #251,785

Re: #251,782: @WorstLuck - RVNC FWIW, I think the selling has gone a

Seeing the right kind of progress at least in Q2 (but preferably over at least two consecutive Q's like I have often said) could start to make it look more like a "value" play.

Sure - but at this point it's clear Foley has zero idea how to manage (eg ALWAYS reactive, and even then in a vague short term way) and the adults are waiting way too late to make a change. It's been happening a lot of places. Eg I follow CARA, which also has a good drug, and they didn't make the obvious prioritizations necessary until there was just barely, if everything goes well, enough money to make it to the end. Zero interest rate allowed the proliferation of inept managers - and they now need to be weeded out. (on CARA - history says they don't have the ability to make the plan go well. Eg they'll like pick a stupid dose to go forward).

Another of this form was RLMD - and they are at least trying now. And they didn't leave it quite so late as RVNC and CARA, but its not clear they have the ability to make good decisions.

dewophile

05/10/24 12:09 PM

Post #251,784

Re: #251,779: @DewDiligence - NVAX—(+130%)—inks SNY collaboration_for COVID and COVID/flu vaccines—$500M up-front cash:

$500M up-front cash

wow and congrats to anyone who is long didn't think they could get an up front like this
SNY must believe either that the NVAX platform can enable you to pick a flu strain on VERY short notice, or that it has some other advantage over MRNA tech, because if anything the one area where mRNA is expected to be better than current vaccines is flu bc you can pick a strain much closer to the flu season

Cmed123

05/10/24 12:00 PM

Post #251,783

its been quite a while since i have been on here....werent you guys all bulled up and long on ENTA and RVNC?
Charts look like complete disasters..... any reasons to be bottom fishing on either name at these levels?

WorstLuck

05/10/24 11:51 AM

Post #251,782

Re: #251,600: @WorstLuck - Please, you tell me why it keeps hitting

RVNC

FWIW, I think the selling has gone a bit too far. But that doesn't mean it can't go lower. Q1 sales are probably priced in. Q2 will be interesting. Early CD sales may be informative, or not. I feel no rush to put on a position for the long term. Buying downtrends isn't what I want to do.

Q1 was kind of in the ballpark of what I was expecting, not knowing how the coupon program was going to play. Q2 is not make-or-break but you might as well treat it that way since the street is long past the benefit-of-doubt stage.

Price has gotten cheap enough that the common has become a leap option with no expiration, but at this point it's still a speculative play rather than a "value" play. Seeing the right kind of progress at least in Q2 (but preferably over at least two consecutive Q's like I have often said) could start to make it look more like a "value" play.

oc631

05/10/24 10:44 AM

Post #251,781

Re: #251,779: @DewDiligence - NVAX—(+130%)—inks SNY collaboration_for COVID and COVID/flu vaccines—$500M up-front cash:

SNY will commercialize NVAX’s existing COVID vaccine and will develop a combination COVID/flu vaccine incorporating NVAX’s “Matrix-M” adjuvant technology

The industry trend of moving towards combo vaccines is lifesaver for NVAX and it will be interesting to see how their adjuvanted vaccine works in combination with a flu vaccine from another developer.

I'm getting deja vu on NVAX promised timelines once again. They supposedly submitted their BLA yet it hasn't been accepted yet. How many years has it been? SNY will take over in "2025" (after approval?) which means if NVAX is granted EUA for the updated seasonal vax they are initially on their own commercially. This is how I read it anyway.

DewDiligence PremiumMember

05/10/24 10:08 AM

Post #251,780

Re: #250,743: @DewDiligence - MRNA has a lot riding on ACIP’s recommendations

FDA delays action date on MRNA’s RSV vaccine:

https://finance.yahoo.com/news/moderna-announces-investigational-rsv-vaccine-110000123.html

Moderna…today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna's investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024. The FDA has not informed Moderna of any issues related to vaccine safety, efficacy or quality that would prevent the approval of mRNA-1345.

Moderna remains on track for mRNA-1345 to be reviewed at the CDC's Advisory Committee on Immunization Practices (ACIP) June 26-27, 2024, meeting, which is necessary prior to commercial launch.

This delay looks like a non-issue as long as FDA approval comes before the ACIP meeting in June. See #msg-173915224 for related info.

DewDiligence PremiumMember

05/10/24 9:54 AM

Post #251,779

Re: #251,694: @oc631 - I don't want you further upsetting NVAX investors

NVAX—(+130%)—inks SNY collaboration_for COVID and COVID/flu vaccines—$500M up-front cash:

https://finance.yahoo.com/news/novavax-sanofi-announce-co-exclusive-060000896.html

SNY will commercialize NVAX’s existing COVID vaccine and will develop a combination COVID/flu vaccine incorporating NVAX’s “Matrix-M” adjuvant technology.

stocksrising Free

05/10/24 7:24 AM

Post #251,778

Ouch!!

https://ih.advfn.com/p.php?pid=nmona&article=93817727

07:12 AM EDT, 05/10/2024 (MT Newswires) -- MacroGenics (MGNX) late on Thursday said that five patients have died in the ongoing mid-stage study of its experimental drug to treat a type of prostate cancer, sending shares down by 65%.

Of the five patients, one died from acute myocardial infarction, one from cardiac arrest, two from pneumonitis, and one due to pleural effusion.

MacroGenics is undertaking the initial steps necessary to prepare for the potential initiation of a Phase 3 study in 2025, but the final decision to pursue the study will be based on an analysis of the final data set when available, the company said.

jbog

05/09/24 8:26 PM

Post #251,777

Re: #251,776: @DewDiligence - That info was from RVNC's CD training program.

Good training session whereas you allow the injector to deviate.

DewDiligence PremiumMember

05/09/24 7:07 PM

Post #251,776

Re: #251,775: @jbog - Your post from Feb lead me to believe

That info was from RVNC's CD training program.

jbog

05/09/24 6:45 PM

Post #251,775

Re: #251,774: @DewDiligence - No Daxxify therapeutics sales were booked in 1Q24.

Your post from Feb lead me to believe that Daxi is being used in the CD field. Foley's comments below wouldn't have been the result of a trial.

RVNC—Cervical-dystonia discussion—and market-share ramifications—from 4Q23 CC:

On today’s CC Foley disclosed that RVNC is seeing excellent results from injectors who are giving CD patients half as much active toxin as these injectors typically give the same CD patients when they are treated with Botox. (I.e. the injectors are dosing 1:1 in labeled numerical units rather than 2:1). On first hearing this I found it astonishing, but after thinking it over I realized that it makes perfect sense.

DewDiligence PremiumMember

05/09/24 6:26 PM

Post #251,774

Re: #251,773: @jbog - Dew 1Q24 Daxxify sales were $22.1M, -8% QoQ —

No Daxxify therapeutics sales were booked in 1Q24. The formal Daxxify launch in cervical dystonia was announced today (#msg-174389042).

1Q24 was a weak quarter for the entire dermal-filler market. ABBV's 1Q24 Juvederm sales were -16% YoY.

jbog

05/09/24 6:08 PM

Post #251,773

Re: #251,765: @DewDiligence - RVNC reports 1Q24 results—reiterates 2024 guidance:

Dew

1Q24 Daxxify sales were $22.1M, -8% QoQ — due to $2.0M of redeemed coupons and normal seasonality in the aesthetics business — and +44% YoY.

I'm sure there has to be some amount of sales attributed to therapeutics. Would you have any guess?

• 1Q24 dermal-filler sales were 29.6M, -14% QoQ and -2% YoY.

Not being familiar with the landscape of fillers, has someone come out with a superior product" If not there must be something wrong with the injectors relationship.

DewDiligence PremiumMember

05/09/24 5:41 PM

Post #251,772

Re: #244,171: @DewDiligence - MGNX inks GILD collaboration_for bispecific mAbs—$60M up-front cash:

MGNX—(-63%/AH)—reports multiple “Grade 5” SAEs in phase-2 trial:

https://finance.yahoo.com/news/macrogenics-provides-corporate-progress-first-200100560.html

A total of five events with fatal outcome occurred as follows: one Grade 5 event in the 2.0 mg/kg dosing cohort: acute myocardial infarction (considered unrelated to study drug by the investigator); three Grade 5 events in the 2.7 mg/kg dosing cohort: one cardiac arrest (considered unrelated to study drug by the investigator) and two events of pneumonitis. In addition, a patient in the 2.7 mg/kg dosing cohort had a Grade 3 pleural effusion that is recorded as having a fatal outcome. The latter three deaths are being investigated, as follow-up is incomplete on this ongoing trial.

MadCityCyclone Free

05/09/24 5:18 PM

Post #251,771

Re: #251,770: @jbog - IOVA just stated they have in excess of

They must have put some thought into how to manage a launch, unlike some companies (looking at you Revance).

Older

Biotech Values

Followers	1523	Posters	2564
Posts (Today)	8	Posts (Total)	251821
Created	11/14/02	Type	Free
Moderator DewDiligence
Assistants Biowatch

Biotech Values is a forum for discussing
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Compilations
Biotech Buyouts/Premiums
Oral Weight-Loss Drugs
Biotech-Newbie Misconceptions (see Reply chain)
Biotech Abbreviations and Acronyms
'Way Back' Archive (Greatest Hits 2003-2009)

Board Info

Posts Today	8
Posts (Total)	251821
Posters	2564
Moderator	DewDiligence
Assistants	Biowatch

New Post

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Biotech Values

Biotech Values

Join the InvestorsHub Community

Biotech Values

Board Info